Date of Award
Open Access Thesis
Master of Medical Science (MMSc)
Sara Schaefer, MD, MHS
Olfaction impairment is one of the earliest nonmotor symptoms of Parkinson’s disease. Olfaction disorders in patients with Parkinson’s disease can range from hyposmia, a reduction in smell ability, to anosmia, a complete loss of smell. Regardless of severity, olfaction loss can result in decreased well-being and mood disorders. However, there is no approved management for anosmia or hyposmia secondary to Parkinson’s disease. Insulin is hypothesized to modulate olfactory neuron regeneration in patients with post-infectious hyposmia, but its effects have not been studied in Parkinson’s patients. Using a randomized controlled trial design, we seek to determine whether eight weeks of daily application of intranasal insulin results in a significant improvement in olfaction performance over baseline in Parkinson’s patients with a 6-month minimum history of anosmia or hyposmia. The results from this study could provide an evidence-based treatment option for this bothersome non-motor symptom, for which there are no treatment options.
Anonye, Eden, "Effect of Intranasal Insulin for Anosmia and Hyposmia in Parkinson’s Patients" (2023). Yale School of Medicine Physician Associate Program Theses. 191.
This Article is Open Access